What Resources are Available to Providers?
In this constantly changing field of cancer treatment, AIM with Immunotherapy makes information about immunotherapies available for healthcare professionals to deliver excellent- quality care. The information on this website is regularly updated to keep providers informed on advances and new approvals. Updates are important, as every year brings new drugs to market to advance patient care in oncology.
Immunotherapies are broadly defined here as:
- Antibody-drug conjugates (ADCs)
- Bispecific antibodies
- Bispecific T-cell engagers (BiTEs)
- Chimeric antigen receptor (CAR) T-cell therapy
- Cytokines
- Immune checkpoint inhibitors (ICIs)
- Monoclonal antibodies
- Oncolytic virotherapy
- Tumor-infiltrating lymphocyte (TIL) therapy
- Vaccines
This section of the AIM with Immunotherapy website features:
- Blog posts on contemporary issues related to the management and understanding of immunotherapy
- Carestep Pathways to recognize and then address immune-related adverse events (irAEs)
- Continuing medical education (CME) opportunities offered through our partnerships
- Drugs listed by tumor type
- Healthcare provider toolkits that provide information on drug management
- Newly-published medical information
- Other resources including ctDNA testing and monitoring for response to immunotherapy, a Facebook provider community, and information on healthcare disparities
- Videos about irAEs from faculty discussing the clinical management and guidance on communicating with patients
Why trust AIM’s resources?
Our resources are written with guidance and assistance from the latest medical information in high-impact medical journals, governing bodies, regulatory agencies, and reputable sources. The initial writing is done at the PhD level and then passed to multiple editors. The polished written content is then thoroughly reviewed by licensed medical professionals who are experts in the specific area of medicine and treatment. Nothing is created in isolation.